Bone and Joint Infection
38
5
6
23
Key Insights
Highlights
Success Rate
96% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
2.6%
1 terminated out of 38 trials
95.8%
+9.3% vs benchmark
11%
4 trials in Phase 3/4
9%
2 of 23 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 23 completed trials
Clinical Trials (38)
Controlled Trial of Omadacycline Randomized Treatment Given for Bone and Joint Infection
Clinical Relevance of Intracellular Staphylococci in BOne and Joint Infections
Ultralow Dose PET Imaging for 18F-NaF Uptake
BonE and Joint Infections - Simplifying Treatment in Children Trial
Comparing Oral Versus Parenteral Antimicrobial Therapy
Ofloxacin Concentration-toxicity Relationship in the Elderly
Oral-only Antibiotics for Bone and Joint Infections in Children
Initial Oral Antibiotics for Bone and Joint Infections in Children
Impact of Pharmaceutical Interviews Regarding the Management of Adverse Effects Related to the Antibiotic Therapy Used to Treat Osteoarticular Infections During Return Home
Tolerability, Safety, and Efficacy of Tedizolid as Oral Treatment for Bone and Joint Infections (OTTER)
Infection After Free Fibula Flap Reconstruction of the Mandible: a Retrospective Cohort Study
Comparison of Two Empirical Antimicrobial Therapies of Prosthetic Joint Infection
Osteoarticular Infections With Pneumococcal
Phage Safety Retrospective Cohort Study
Prognostic Impact of Delta-haemolysin Production Deficiency in Staphylococcus Aureus on the Prognosis of Infected Implant Treated by DAIR
Periarticular Penetration of Cefazolin and Clindamycin in Second Stage Revision Arthroplasty of the Hip
Pharmacokinetics and Toxicodynamics of Daptomycin in Bone and Joint Infections
Recurrent S. Aureus Infections in Osteoarticular Infections
Lyon PJI Retrospective Cohort Study
Septic Management and Outcome of Open Fracture